Lipid Metabolism Practice Questions

Q: What is the mechanism for the transport of fatty acids across the mitochondrial membrane?

Facilitated transport. **Explanation:** The transport of long-chain fatty acids (LCFA) into the mitochondria is the rate-limiting step of **$\beta$-oxidation**. While short and medium-chain fatty acids can cross the mitochondrial membranes directly, LCFAs require a specialized shuttle system known as the **Carnitine Shuttle**. **Why Facilitated Transport is Correct:** The Carnitine Shuttle utilizes specific carrier proteins to move fatty acyl-CoA molecules across the inner mitochondrial membrane. This process involves **Carnitine Palmitoyltransferase I (CPT-I)** on the outer membrane and **CPT-II** on the inner membrane, along with a **Carnitine-acylcarnitine translocase**. Because this movement depends on specific membrane-bound transporters to move molecules across a biological membrane, it is classified as **facilitated transport**. **Analysis of Incorrect Options:** * **Active Transport:** This requires direct ATP hydrolysis to move solutes against a concentration gradient. The carnitine shuttle is a facilitated exchange mechanism, not a primary active pump. * **Diffusion:** LCFAs are too large and polar (when activated to Acyl-CoA) to freely diffuse through the impermeable inner mitochondrial membrane. * **Lipases:** These are enzymes (like Hormone-Sensitive Lipase) that hydrolyze triglycerides into free fatty acids and glycerol; they are not transport mechanisms. **High-Yield Clinical Pearls for NEET-PG:** * **Inhibitor:** **Malonyl-CoA** (the first intermediate of fatty acid synthesis) potently inhibits **CPT-I**, preventing a futile cycle where synthesis and oxidation occur simultaneously. * **Carnitine Deficiency:** Presents with non-ketotic hypoglycemia, muscle weakness, and cardiomyopathy during fasting. * **Location:** CPT-I is located in the outer mitochondrial membrane, while CPT-II is in the inner mitochondrial membrane.

Q: Acetyl-CoA generated from the metabolism of fatty acids can be converted into all of the following, except:

Glucose. **Explanation:** The conversion of Acetyl-CoA to glucose is impossible in humans because the **Pyruvate Dehydrogenase (PDH) complex reaction is irreversible**. 1. **Why Glucose is the correct answer:** In the metabolic pathway, Pyruvate is converted to Acetyl-CoA by the PDH complex. However, there is no enzyme in human tissues that can convert Acetyl-CoA back into Pyruvate or Oxaloacetate (net gain). While Acetyl-CoA enters the TCA cycle by condensing with Oxaloacetate, two carbons are lost as $CO_2$ during the cycle. Consequently, there is **no net synthesis of glucose** from Acetyl-CoA. This is why fatty acids (which break down into Acetyl-CoA) cannot be used for gluconeogenesis. 2. **Analysis of Incorrect Options:** * **Fatty Acids:** Acetyl-CoA is the primary substrate for fatty acid synthesis (Lipogenesis) via its conversion to Malonyl-CoA in the cytoplasm. * **Cholesterol:** Acetyl-CoA is the precursor for the entire steroid synthesis pathway. Two molecules of Acetyl-CoA form Acetoacetyl-CoA, eventually leading to HMG-CoA and then Mevalonate (the rate-limiting step of cholesterol synthesis). * **Ketone Bodies:** During starvation or uncontrolled diabetes, excess Acetyl-CoA from $\beta$-oxidation is diverted to Ketogenesis in the liver mitochondria to form Acetoacetate and $\beta$-hydroxybutyrate. **High-Yield Clinical Pearls for NEET-PG:** * **Odd-chain fatty acids** are the exception: Their metabolism yields **Propionyl-CoA**, which enters the TCA cycle as Succinyl-CoA and *can* be converted to glucose. * **Leucine and Lysine** are purely ketogenic amino acids because they are metabolized directly to Acetyl-CoA or Acetoacetate. * The **PDH complex** requires five cofactors: Thiamine ($B_1$), Riboflavin ($B_2$), Niacin ($B_3$), Pantothenic acid ($B_5$), and Lipoic acid.

Q: How do long-chain fatty acids enter the mitochondria?

By combining with carnitine. **Explanation:** The entry of long-chain fatty acids (LCFAs) into the mitochondria is the rate-limiting step of **beta-oxidation**. While short-chain and medium-chain fatty acids can diffuse freely, LCFAs cannot cross the impermeable inner mitochondrial membrane (IMM) on their own. **Why Option C is correct:** To cross the IMM, LCFAs must undergo the **Carnitine Shuttle**. First, they are activated to Fatty Acyl-CoA in the cytosol. The enzyme **Carnitine Palmitoyltransferase-I (CPT-I)** then replaces the CoA group with **carnitine**, forming Acyl-carnitine. This complex is transported across the IMM by a translocase. Once inside the matrix, **CPT-II** converts it back into Fatty Acyl-CoA and free carnitine. **Why other options are incorrect:** * **Options A & B:** The outer mitochondrial membrane contains porins (VDAC) that allow many molecules to pass, but the **inner membrane** is highly selective and lacks pores for fatty acids. Transport requires specific protein carriers. * **Option D:** **Ornithine** is an amino acid involved in the **Urea Cycle**, not lipid metabolism. It helps transport nitrogenous waste, not fatty acids. **High-Yield Clinical Pearls for NEET-PG:** * **Inhibitor:** **Malonyl-CoA** (the first intermediate of fatty acid synthesis) potently inhibits CPT-I. This prevents a "futile cycle" by ensuring synthesis and breakdown do not occur simultaneously. * **Systemic Carnitine Deficiency:** Presents with non-ketotic hypoglycemia, muscle weakness, and liver dysfunction because the body cannot utilize LCFAs for energy during fasting. * **Location:** CPT-I is located on the outer mitochondrial membrane; CPT-II is on the inner mitochondrial membrane.

Q: Which apolipoprotein is associated with Alzheimer's disease?

APOE4. **Explanation:** The correct answer is **APOE4**. Apolipoprotein E (ApoE) is a critical glycoprotein involved in the transport of lipids and cholesterol within the central nervous system. In humans, the APOE gene exists in three common alleles: ε2, ε3, and ε4. **Why APOE4 is correct:** The **APOE-ε4** allele is the strongest genetic risk factor for late-onset **Alzheimer’s Disease (AD)**. Mechanistically, ApoE4 is less efficient than other isoforms at clearing amyloid-beta (Aβ) peptides from the brain. This leads to increased Aβ aggregation and the formation of senile plaques, a hallmark of AD pathology. Carrying one copy of ε4 increases risk 3-fold, while two copies increase risk up to 12-fold. **Analysis of Incorrect Options:** * **APOE1:** This is not a common functional isoform in the human population and is not clinically relevant to Alzheimer’s risk. * **APOE2:** This isoform is actually considered **protective** against Alzheimer’s disease. However, it is associated with an increased risk of Type III Hyperlipoproteinemia (Dysbetalipoproteinemia). * **APOE3:** This is the most common (wild-type) isoform in the general population. It is considered "neutral" regarding Alzheimer’s risk. **High-Yield Clinical Pearls for NEET-PG:** * **ApoE Function:** It serves as a ligand for the LDL receptor, facilitating the uptake of chylomicron remnants and VLDL. * **Type III Hyperlipoproteinemia:** Associated with **ApoE2** homozygosity, resulting in elevated cholesterol and triglycerides due to poor clearance of IDL and remnants. * **Alzheimer’s Pathology:** Remember the "Amyloid Cascade Hypothesis"—ApoE4 promotes amyloid deposition and neurofibrillary tangles (Tau protein). * **Protective Factor:** APOE2 is the "good" allele for the brain; APOE4 is the "bad" allele.

Q: What is the primary enzymatic conversion performed by aromatase?

Androgen to estrogen. **Explanation:** **Aromatase** (also known as estrogen synthase or CYP19A1) is a member of the Cytochrome P450 superfamily. Its primary function is the conversion of **androgens to estrogens**. Specifically, it catalyzes the aromatization of the 'A' ring of the steroid nucleus, converting **androstenedione to estrone** and **testosterone to estradiol**. This process involves three successive hydroxylation steps requiring NADPH and molecular oxygen. **Analysis of Options:** * **Option B (Correct):** Aromatase is the rate-limiting enzyme that transforms C19 steroids (androgens) into C18 steroids (estrogens) by removing a methyl group and creating an aromatic ring. * **Option A:** This is the reverse process. Androgens are precursors to estrogens; there is no direct enzymatic pathway for aromatase to convert estrogens back into androgens. * **Option C:** Progesterone is a C21 steroid. It must first be converted to androgens (via 17α-hydroxylase and 17,20-lyase) before it can be converted to estrogens. * **Option D:** Androgens are downstream of progesterone in the steroidogenic pathway. **High-Yield Clinical Pearls for NEET-PG:** * **Localization:** Aromatase is highly expressed in the granulosa cells of the ovaries, adipose tissue, placenta, and the brain. * **Clinical Application:** **Aromatase Inhibitors** (e.g., Letrozole, Anastrozole, Exemestane) are first-line treatments for hormone-receptor-positive breast cancer in postmenopausal women. * **Aromatase Deficiency:** A rare condition leading to virilization of the female fetus and maternal virilization during pregnancy (due to the inability of the placenta to convert fetal androgens to estrogens). * **PCOS Connection:** In Polycystic Ovary Syndrome, there is often an altered LH/FSH ratio leading to relative aromatase inactivity in granulosa cells, contributing to hyperandrogenism.

Q: Which of the following is a primary ketone body that is formed from leucine, lysine, phenylalanine, and tyrosine?

Acetoacetate. **Explanation:** The synthesis of ketone bodies (ketogenesis) occurs primarily in the liver mitochondria. The process begins with the condensation of acetyl-CoA molecules to form **Acetoacetate**, which is the **first and primary ketone body** produced. **Why Acetoacetate is correct:** Ketogenic amino acids (Leucine and Lysine) and partially ketogenic amino acids (Phenylalanine and Tyrosine) are catabolized into either Acetyl-CoA or Acetoacetyl-CoA. These precursors enter the HMG-CoA pathway to form Acetoacetate. Because Acetoacetate is the parent molecule from which other ketone bodies are derived, it is considered the primary ketone body formed during the breakdown of these amino acids. **Why other options are incorrect:** * **B. Acetone:** This is a secondary ketone body formed by the non-enzymatic, spontaneous decarboxylation of acetoacetate. It is a waste product excreted via the lungs (causing "fruity breath"). * **C. Beta-hydroxybutyrate:** This is formed from the reduction of acetoacetate by the enzyme *β-hydroxybutyrate dehydrogenase*. While it is the predominant ketone body in the blood during ketosis, it is a secondary derivative, not the initial product. * **D. All of the above:** While all three are ketone bodies, only acetoacetate is the direct primary product formed from the ketogenic skeletons of the listed amino acids. **High-Yield NEET-PG Pearls:** * **Purely Ketogenic Amino Acids:** Leucine and Lysine (The "L"s). * **Rate-limiting enzyme of Ketogenesis:** HMG-CoA Synthase (Mitochondrial). * **Site of Utilization:** Ketone bodies are used by extrahepatic tissues (brain, heart, muscle) but **not by the liver**, because the liver lacks the enzyme **Thiophorase** (Succinyl-CoA:3-ketoacid CoA transferase). * **Detection:** The Rothera’s test detects Acetoacetate and Acetone, but **not** Beta-hydroxybutyrate.

Q: Which of the following is a glycosphingolipid?

Sphingomyelin. ### Explanation **Correct Answer: D. Sphingomyelin** **Concept:** Lipids are classified based on their backbone. **Sphingolipids** contain a complex amino alcohol called **sphingosine** instead of glycerol. Sphingomyelin is a unique phospholipid because it is the only sphingolipid that contains **phosphate** (as phosphorylcholine) but no sugar. While the question asks for a glycosphingolipid, in many standard medical classifications and exam contexts, Sphingomyelin is grouped under the broader category of sphingolipids due to its sphingosine backbone, distinguishing it from glycerol-based lipids. *Note: Strictly speaking, glycosphingolipids (like Cerebrosides and Gangliosides) contain carbohydrates. However, among the given options, Sphingomyelin is the only one belonging to the Sphingolipid family.* **Analysis of Incorrect Options:** * **A. Lecithin (Phosphatidylcholine):** This is a **glycerophospholipid**. It consists of a glycerol backbone, two fatty acids, and a choline group attached to a phosphate. * **B. Cardiolipin (Diphosphatidylglycerol):** Found exclusively in the inner mitochondrial membrane. It consists of two molecules of phosphatidic acid connected by a glycerol bridge. * **C. Plasmalogens:** These are specialized ether lipids where the fatty acid at the C1 position of glycerol is attached via an **ether linkage** (alkenyl group) rather than an ester bond. **High-Yield NEET-PG Pearls:** * **Niemann-Pick Disease:** Caused by a deficiency of **Sphingomyelinase**, leading to the accumulation of sphingomyelin in the liver, spleen, and brain (look for "Cherry Red Spot" on the macula). * **Surfactant:** Lecithin (Dipalmitoylphosphatidylcholine) is the major component of lung surfactant; an L/S ratio > 2 indicates fetal lung maturity. * **Barth Syndrome:** A rare X-linked disorder associated with abnormal cardiolipin metabolism, leading to cardiomyopathy.

Q: What is the best predictor for coronary artery disease?

LDL. **Explanation:** **Why LDL is the correct answer:** Low-Density Lipoprotein (LDL) is the primary carrier of cholesterol from the liver to peripheral tissues. It is considered the most significant independent risk factor and the **best predictor** for Coronary Artery Disease (CAD) because it is highly atherogenic. When LDL levels are elevated, they infiltrate the arterial intima, undergo oxidation, and are engulfed by macrophages to form "foam cells," the hallmark of atherosclerotic plaques. Clinical management of CAD primarily targets the lowering of LDL-C levels. **Analysis of Incorrect Options:** * **HDL (High-Density Lipoprotein):** Known as "good cholesterol," HDL facilitates reverse cholesterol transport (carrying cholesterol back to the liver). While low HDL is a risk factor, high levels are actually **cardioprotective**. * **VLDL (Very Low-Density Lipoprotein):** VLDL primarily transports endogenous triglycerides. While elevated VLDL contributes to metabolic syndrome, it is a precursor to LDL and not as direct a predictor of CAD as LDL itself. * **Chylomicrons:** These transport dietary (exogenous) triglycerides from the intestines. They are the least dense lipoproteins and are not directly implicated in the pathogenesis of atherosclerosis. **NEET-PG High-Yield Pearls:** * **Friedewald Formula:** LDL = Total Cholesterol – [HDL + (Triglycerides/5)]. (Note: This is invalid if TG >400 mg/dL). * **Apo-B100:** The characteristic apoprotein found in VLDL, IDL, and LDL. It is often cited as an even more precise marker of atherogenic particles than LDL-C. * **Lipoprotein (a):** An independent genetic risk factor for CAD; it is essentially an LDL particle with an attached Apo(a). * **Oxidized LDL:** The specific form of LDL that is most toxic to the endothelium and leads to plaque formation.

Q: Which of the following lipids is associated with respiratory distress syndrome?

Dipalmitoyl lecithin. ### Explanation **Correct Option: C. Dipalmitoyl lecithin** **Mechanism and Clinical Correlation:** Respiratory Distress Syndrome (RDS), specifically Neonatal RDS (Hyaline Membrane Disease), is caused by a deficiency of **pulmonary surfactant**. Surfactant is a lipoprotein complex synthesized by **Type II pneumocytes**. Its primary function is to reduce surface tension at the alveolar air-liquid interface, preventing alveolar collapse (atelectasis) during expiration. The major lipid component of surfactant (comprising about 80%) is phospholipids, and the most abundant and active constituent is **Dipalmitoylphosphatidylcholine (DPPC)**, also known as **Dipalmitoyl lecithin**. It acts as a detergent; its amphipathic nature allows it to spread across the alveoli, lowering the pressure required to keep them inflated. **Analysis of Incorrect Options:** * **A. Phosphatidylethanolamine (Cephalin):** Found primarily in nervous tissue and cell membranes; it is not a major component of lung surfactant. * **B. Phosphatidylserine:** Important for cell signaling and apoptosis (it flips to the outer leaflet to signal "eat me" to macrophages), but plays no role in surface tension reduction. * **D. Phosphatidylinositol:** A precursor for second messengers like $IP_3$ and $DAG$; while present in small amounts in surfactant, it is not the primary functional lipid associated with RDS. **High-Yield NEET-PG Pearls:** * **L/S Ratio:** Fetal lung maturity is assessed via the **Lecithin/Sphingomyelin ratio** in amniotic fluid. A ratio **> 2.0** indicates mature lungs. * **Glucocorticoids:** Given to mothers in preterm labor (e.g., Betamethasone) to stimulate surfactant production by inducing fibroblast pneumocyte factor. * **Surfactant Proteins:** SP-A and SP-D are involved in innate immunity, while **SP-B and SP-C** are crucial for the mechanical spreading of the surfactant film. Deficiency of SP-B is a rare genetic cause of RDS.

Q: Ketone bodies are synthesized in which part of the body?

Liver. **Explanation:** **1. Why the Liver is Correct:** Ketone bodies (Acetoacetate, 3-hydroxybutyrate, and Acetone) are synthesized primarily in the **mitochondria of liver hepatocytes**. This process, known as ketogenesis, occurs when there is an excess of Acetyl-CoA (derived from fatty acid β-oxidation) that cannot enter the TCA cycle due to a depletion of oxaloacetate (e.g., during starvation or uncontrolled diabetes). The rate-limiting enzyme for this process is **HMG-CoA synthase**, which is highly expressed in the liver. **2. Why Other Options are Incorrect:** * **Brain & Heart (Options A & C):** These organs are major **consumers** of ketone bodies, not producers. While the brain normally relies on glucose, it adapts to use ketones during prolonged fasting. The heart prefers fatty acids but can readily oxidize ketones. They lack the enzymatic machinery for synthesis. * **Intestine (Option D):** While the intestinal mucosa can produce small amounts of ketones during development or specific dietary states, it is not a primary site of synthesis and is clinically insignificant compared to the liver. **3. High-Yield Clinical Pearls for NEET-PG:** * **The "Liver Paradox":** Although the liver synthesizes ketone bodies, it **cannot utilize them** because it lacks the enzyme **Thiophorase** (Succinyl-CoA:3-ketoacid CoA transferase). * **Ketone Body Ratio:** The ratio of 3-hydroxybutyrate to acetoacetate depends on the NADH/NAD+ ratio in the mitochondria. * **Detection:** The **Rothera’s Test** detects Acetoacetate and Acetone, but **not** 3-hydroxybutyrate. * **Key Enzyme:** HMG-CoA **Synthase** is for Ketogenesis; HMG-CoA **Reductase** is for Cholesterol synthesis.

Question 1

What is the mechanism for the transport of fatty acids across the mitochondrial membrane?

Accepted Answer

Facilitated transport

Answer

Active transport

Answer

Diffusion

Answer

Lipases

Question 2

Acetyl-CoA generated from the metabolism of fatty acids can be converted into all of the following, except:

Accepted Answer

Glucose

Answer

Fatty Acids

Answer

Cholesterol

Answer

Ketone bodies

Question 3

How do long-chain fatty acids enter the mitochondria?

Accepted Answer

By combining with carnitine

Answer

Through pores in the inner mitochondrial membrane

Answer

Through pores in the outer mitochondrial membrane

Answer

By combining with ornithine

Question 4

Which apolipoprotein is associated with Alzheimer's disease?

Accepted Answer

APOE4

Answer

APOE1

Answer

APOE2

Answer

APOE3

Question 5

What is the primary enzymatic conversion performed by aromatase?

Accepted Answer

Androgen to estrogen

Answer

Estrogen to androgen

Answer

Progesterone to estrogen

Answer

Androgen to progesterone

Question 6

Which of the following is a primary ketone body that is formed from leucine, lysine, phenylalanine, and tyrosine?

Accepted Answer

Acetoacetate

Answer

Acetone

Answer

Beta-hydroxybutyrate

Answer

All of the above

Question 7

Which of the following is a glycosphingolipid?

Accepted Answer

Sphingomyelin

Answer

Lecithin

Answer

Cardiolipin

Answer

Plasmalogens

Question 8

What is the best predictor for coronary artery disease?

Accepted Answer

LDL

Answer

HDL

Answer

VLDL

Answer

Chylomicron

Question 9

Which of the following lipids is associated with respiratory distress syndrome?

Accepted Answer

Dipalmitoyl lecithin

Answer

Phosphatidylethanolamine (cephalin)

Answer

Phosphatidylserine

Answer

Phosphatidylinositol

Question 10

Ketone bodies are synthesized in which part of the body?

Accepted Answer

Liver

Answer

Brain

Answer

Heart

Answer

Intestine

Lipid Metabolism — MCQs

Lipid Metabolism — MCQs

On this page

Practice by Chapter

Want unlimited practice?